Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial.
Am J Psychiatry
January 2025
Institute for Advanced Diagnostics and Treatment, Sheppard Pratt Health System, Baltimore (Aaronson, Miller, LaPratt, Swartz, Shoultz, Lauterbach); Department of Psychiatry, University of Maryland, Baltimore (Aaronson, van der Vaart, Lauterbach); VA Palo Alto Health Care System and Department of Psychiatry and Behavioral Sciences Stanford University School of Medicine, Palo Alto, CA (Suppes); Departments of Psychiatry and Radiology, Columbia University, New York (Sackeim).
Article Synopsis
- The study focused on evaluating the safety and effectiveness of psilocybin for patients with severe treatment-resistant depression (TRD), who had not benefited from at least five previous treatments.
- Conducted over 12 weeks at Sheppard Pratt Hospital, patients received a single 25 mg dose of synthetic psilocybin and underwent therapy sessions before and after dosing, assessing their depression levels mainly with the Montgomery-Åsberg Depression Rating Scale (MADRS).
- Results showed significant reductions in depressive symptoms at both 3 weeks and 12 weeks post-treatment, indicating psilocybin’s potential as a viable option for individuals with severe TRD, although those with comorbid PTSD experienced less improvement.
Treatment access gap during the COVID-19 Pandemic: impact on problematic alcohol use and the moderating roles of perceived stress and resilience.
Front Psychiatry
December 2024
Office of the Clinical Director, DICBR, NIAAA, Bethesda, MD, United States.
Objective: The COVID-19 pandemic may have interfered with individuals' access to alcohol use disorder (AUD) treatment, but limited research has documented the impact of treatment interference on drinking behavior. This study's purpose was to examine the associations of AUD treatment interference with problematic alcohol use, and the moderating roles of perceived stress and resilience.
Method: A cross-sectional survey design was employed.
International workshop: what is needed to ensure outcome measures for Rett syndrome are fit-for-purpose for clinical trials? June 7, 2023, Nashville, USA.
Trials
December 2024
School of Medicine Depts of Pediatrics, Neurology and Pharmacology, Children's Hospital Colorado/University of Colorado, 12800 E 19th, MS8102, Aurora, CO, 80045, USA.
Introduction: The clinical, research and advocacy communities for Rett syndrome are striving to achieve clinical trial readiness, including having fit-for-purpose clinical outcome assessments. This study aimed to (1) describe psychometric properties of clinical outcome assessment for Rett syndrome and (2) identify what is needed to ensure that fit-for-purpose clinical outcome assessments are available for clinical trials.
Methods: Clinical outcome assessments for the top 10 priority domains identified in the Voice of the Patient Report for Rett syndrome were compiled and available psychometric data were extracted.
The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.
J Affect Disord
March 2025
Compass Pathfinder Ltd (a subsidiary of Compass Pathways plc), London, UK.
Objective: To determine the relationships between psilocybin dose, psychedelic experiences, and therapeutic outcome in treatment-resistant depression.
Methods: For treatment-resistant depression, 233 participants received a single dose of 25, 10, or 1 mg of COMP360 psilocybin (a proprietary, pharmaceutical-grade synthesized psilocybin formulation, developed by the sponsor, Compass Pathfinder Ltd.) with psychological support.
Prescribing of antipsychotics for people diagnosed with severe mental illness in UK primary care 2000-2019: 20-year investigation of who receives treatment, with which agents and at what doses.
Br J Psychiatry
December 2024
Division of Psychiatry, University College London, London, UK.
Background: Contemporary data relating to antipsychotic prescribing in UK primary care for patients diagnosed with severe mental illness (SMI) are lacking.
Aims: To describe contemporary patterns of antipsychotic prescribing in UK primary care for patients diagnosed with SMI.
Method: Cohort study of patients with an SMI diagnosis (i.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!